InvestorsHub Logo
Post# of 252642
Next 10
Followers 831
Posts 120081
Boards Moderated 16
Alias Born 09/05/2002

Re: DewDiligence post# 195304

Friday, 01/08/2016 3:42:12 PM

Friday, January 08, 2016 3:42:12 PM

Post# of 252642
(GLPG/GILD)—ABBV discloses phase-3 program for ABT-494 JAK1 inhibitor in RA:

http://finance.yahoo.com/news/abbvie-announces-launch-robust-phase-140000828.html

All told, there will be five phase-3 trials with more than 4,000 patients.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.